Clinical Trials
10 trialsNCT01087294 2026-06-01
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03068819 2026-04-24
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant
Washington University School of Medicine
Phase 1/2 Completed
NCT00968760 2023-12-19
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02639559 2023-11-07
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
Phase 2 Completed
NCT01653717 2017-08-17
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00968630 2017-05-24
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed
NCT00914849 2017-05-17
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Washington University School of Medicine
Phase 2 Completed
NCT02842112 2016-07-25
Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia
Hospices Civils de Lyon
Completed
NCT01413568 2016-02-26
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Polyphor Ltd.
Phase 1/2 Completed